Drug Profile
CC 671
Alternative Names: CC-671Latest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Celgene Corporation
- Class Antineoplastics; Pyrimidines; Pyrroles; Small molecules
- Mechanism of Action Phosphotransferase inhibitors; TTK protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Triple negative breast cancer
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for preclinical development in Triple negative Breast-cancer in USA
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
- 30 Oct 2017 Preclinical data in Cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017 (AACR-NCI-EORTC-2017)